Skip to main content

Plasma Pentraxin 3 as a Biomarker of Metabolic Syndrome

The Indian Journal of Pediatrics volume 82, pages 35–38 (2015)Cite this article

Abstract

Objective

To assess the plasma Pentraxin 3 (PTX3) concentrations in obese children and to investigate the relationship between PTX3 levels and metabolic syndrome (MS) components.

Methods

Seventy-seven obese patients aged 10–16 y (38 girls, 39 boys) were included in the study. PTX3 levels were compared between the groups with or without MS. In addition, PTX3 was analysed separately by subgroups according to the presence of specific MS components.

Results

Plasma PTX3 concentrations were significantly higher in obese children and adolescents with metabolic syndrome than in those without MS (2.1 ± 1.2 ng/ml and 1.4 ± 0.9 ng/ml respectively; P = 0.02). Patients with low HDL levels (<40 mg/dl) had higher plasma PTX3 concentrations than those with normal HDL levels (P = 0.05). Similarly, those who had high triglyceride levels (≥150 mg/dl) had higher PTX3 levels (P = 0.01). PTX3 levels were negatively correlated with HDL cholesterol (r = −0.32, P = 0.003) among all patients.

Conclusions

PTX3 levels are higher in obese children and adolescents with metabolic syndrome than in those without MS. Thus, PTX3 levels might be a useful biomarker for children and adolescents with metabolic syndrome, dyslipidemia, and cardiovascular risks.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Rolland-Cachera MF. Childhood obesity: current definitions and recommendations for their use. Int J Pediatr Obes. 2011;6:325–31.

    PubMed  Article  Google Scholar 

  2. Itagi V, Patil R. Obesity in children and adolescents and its relationship with hypertension. Turk J Med Sci. 2011;41:259–66.

    Google Scholar 

  3. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;12:1785–8.

    Article  Google Scholar 

  4. Ogawa T, Kawano Y, Imamura T, Kawakita K, Sagara M, Matsuo T, et al. Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity. 2010;18:1871–4.

    CAS  PubMed  Article  Google Scholar 

  5. Abderrahim-Ferkoune A, Bezy O, Chiellini C, Maffei M, Grimaldi P, Bonino F, et al. Characterization of the long pentraxin PTX3 as a TNF alpha-induced secreted protein of adipose cells. J Lipid Res. 2003;44:994–1000.

    CAS  PubMed  Article  Google Scholar 

  6. Alberti L, Gilardini L, Zulian A, Micheletto G, Peri G, Doni A, et al. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis. 2009;202:455–60.

    CAS  PubMed  Article  Google Scholar 

  7. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–66.

    CAS  PubMed  Article  Google Scholar 

  8. Chu SH, Park JH, Lee MK, Jekal Y, Ahn KY, Chung JY, et al. The association between pentraxin 3 and insulin resistance in obese children at baseline and after physical activity intervention. Clin Chim Acta. 2012;413:1430–7.

    CAS  PubMed  Article  Google Scholar 

  9. Shim BJ, Jeon HK, Lee SJ, Kim SS, Park MY, Lee DH, et al. The relationship between serum pentraxin 3 and central obesity in st-segment elevation myocardial infarction patients. Korean Circ J. 2010;40:308–13.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  10. Ozturk A, Mazicioglu MM, Hatipoglu N, Budak N, Keskin G, Yazlak Z, et al. Reference body mass index curves for Turkish children 6–18 y of age. J Pediatr Endocrinol Metab. 2008;21:827–36.

    PubMed  Article  Google Scholar 

  11. Hatipoglu N, Ozturk A, Mazicioglu MM, Kurtoglu S, Seyhan S, Lokoglu F. Waist circumference percentiles for 7–17-y-old Turkish children and adolescents. Eur J Pediatr. 2008;167:383–9.

    PubMed  Article  Google Scholar 

  12. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents—an IDF concensus report. Pediatr Diabetes. 2007;8:299–306.

    PubMed  Article  Google Scholar 

  13. Inokuchi M, Matsuo N, Anzo M, Takayama JI, Hasegawa T. Age- dependent percentile for waist circumference for Japanese children based on the 1992–1994 cross-sectional national survey data. Eur J Pediatr. 2007;166:655–61.

    PubMed  Article  Google Scholar 

  14. Zanetti M, Bosutti A, Ferreira C, Vinci P, Biolo G, Fonda M, et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med. 2009;9:243–8.

    CAS  PubMed  Article  Google Scholar 

  15. Miyaki A, Maeda S, Yoshizawa M, Misono M, Sasai H, Shimojo N, et al. Is pentraxin 3 involved in obesity-induced decrease arterial distensibility? J Atheroscler Thromb. 2010;17:278–84.

    CAS  PubMed  Article  Google Scholar 

  16. Boehme M, Kaehne F, Kuehne A, Bernhardt W, Schröder M, Pommer W, et al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant. 2007;22:2224–9.

    CAS  PubMed  Article  Google Scholar 

  17. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008;155:75–81.

    CAS  PubMed  Article  Google Scholar 

  18. Karakas MF, Buyukkaya E, Kurt M, Motor S, Akcay AB, Karakas E, et al. Serum pentraxin-3 levels are associated with the severity of metabolic syndrome. Med Princ Pract. 2013;22:274–9.

    PubMed  Article  Google Scholar 

  19. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006;45:326–30.

    CAS  PubMed  Article  Google Scholar 

  20. Napoleone E, Di Santo A, Bastone A, Peri G, Mantovani A, de Gaetano G, et al. Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol. 2002;22:782–7.

    CAS  PubMed  Article  Google Scholar 

  21. Witasp A, Carrero JJ, Michaëlsson K, Ahlström H, Kullberg J, Adamsson V, et al. Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots, and weight loss. Obesity. Published Online First. 2014. doi: 10.1002/oby.20695.

  22. Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G, et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis. 2004;175:221–8.

    CAS  PubMed  Article  Google Scholar 

  23. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from framingham to the veterans affairs high-density lipoprotein intervention trial. Am J Cardiol. 2000;86:S19–22.

    Article  Google Scholar 

  24. Osorio-Conles O, Guitart M, Chacón MR, Maymo-Masip E, Moreno-Navarrete JM, Montori-grau M, et al. Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, where as visceral adipose tissue PTX3 gene expression is increased in obesity. Am J Physiol Endocrinol Metab. 2011;301:1254–61.

    Article  Google Scholar 

  25. Aydogdu A, Tasci I, Tapan S, Basaran Y, Aydogan U, Meric C. High plasma level of long Pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2012;28:722–5.

    CAS  PubMed  Article  Google Scholar 

Download references

Acknowledgments

The authors thank Prof. Dr. Sebahattin Muhtaroglu for performing analyses in the biochemistry laboratory of Erciyes University, Medical Faculty.

Conflict of Interest

None.

Source of Funding

Health Goverment of Turkey provided financial help to conduct the study.

Author information

Affiliations

  1. Department of Pediatric Nutrition and Metabolism, Erciyes University, 38039, Kayseri, Turkey

    Fatih Kardas

  2. Department of Pediatric Endocrinology, Erciyes University, Kayseri, Turkey

    Leyla Akın, Selim Kurtoglu & Mustafa Kendirci

  3. Department of Pediatrics, State Educational and Research Hospital of the Government, Kayseri, Turkey

    Zehra Kardas

Authors
  1. Fatih Kardas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leyla Akın
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Selim Kurtoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mustafa Kendirci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zehra Kardas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fatih Kardas.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kardas, F., Akın, L., Kurtoglu, S. et al. Plasma Pentraxin 3 as a Biomarker of Metabolic Syndrome. Indian J Pediatr 82, 35–38 (2015). https://doi.org/10.1007/s12098-014-1542-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-014-1542-0

Keywords

  • Pentraxin 3
  • Metabolic syndrome
  • Children
  • Adolescents